Please login to the form below

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched
FDA fast-tracks Bayer's prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review
Bayer points to four blockbusters in portfolio

Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.
Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Director – UK Office: Excellent salary and benefits

Account Director: £Competitive Salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Account Manager: Salary TBC

Account Manager: £Competitive Salary

Senior External Communications Lead: £Competitive Salary

Account Manager (PR): Great Benefits

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

PMHub

Add my company

mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?: Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma funding and M&A in 2020: Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?: Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...